%D9%86%D9%8A%D9%81%D9%88%D8%B1%D8%AA%D9%8A%D9%85%D9%88%D9%83%D8%B3Category:NifurtimoxNifurtimoxNifurtimoxNifurtimoxNifurtimoksiNifurtimoxNifurtimox%E3%83%8B%E3%83%95%E3%83%AB%E3%83%81%E3%83%A2%E3%83%83%E3%82%AF%E3%82%B9%E0%AC%A8%E0%AC%BF%E0%AC%AB%E0%AD%81%E0%AC%B0%E0%AD%8D%E0%AC%9F%E0%AC%BF%E0%AC%AE%E0%AC%95%E0%AD%8D%E0%AC%B8NifurtymoksNifurtimoxNifurtimoksNifurtimoksNifurtimoxQ411582%E7%A1%9D%E5%91%8B%E8%8E%AB%E5%8F%B8
about
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, UgandaSafety Study of Nifurtimox for Relapsed or Refractory NeuroblastomaStudy to Assess Bioequivalence of a New Nifurtimox Oral Tablet FormulationStudy on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in ArgentinaNifurtimox Versus Benznidazole, Retrospective Cohort
P4844
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialAn open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central ZaireSafety Profile of Nifurtimox for Treatment of Chagas Disease in the United StatesEquivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sicknessTolerance and safety of nifurtimox in patients with chronic chagas diseaseNifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case seriesUntargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma bruceiGenome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6.Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment.The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatmentEvaluation of nifurtimox for potential use in control of histomoniasis in turkeys.In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatmentFollow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune responseNegativation of Trypanosoma cruzi PCR within Six Months after Treatment of a Child with NifurtimoxEnantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivoNifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian AdultsA mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.The effects of some drugs--pentamidine, stibocaptate, Hoechst 33258, F 151, compound 'E' and Nifurtimox--on Onchocerca volvulus in chimpanzees.Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomesDisposition of nifurtimox and metabolite activity against Trypanosoma cruzi using rat isolated perfused liver.Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods.First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriers[Nifurtimox, a bright future for treatment of Chagas disease].Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole.Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma.Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).Tissue-reacting antibodies (EVI antibodies) in nifurtimox-treated patients with Chagas's disease.[Chagas' disease caused by blood transfusion in Londrina, Paraná. Report of 2 acute cases treated with nifurtimox]Antiparasitic prodrug nifurtimox: revisiting its activation mechanism.
P921
Q28250035-39597707-8E4B-47B8-A476-47BF1F269C80Q28273902-649F6D32-9CF7-43F1-B832-F3E7E662D28AQ28277238-8DC21A23-39D6-4F0D-9015-F37985E3AD2CQ28281992-2F8DA852-B944-4A73-9D2A-F0B121B4F775Q28295159-DBE24772-5531-483A-A89E-9188C5D4D764Q28471706-FB04C3E3-3D6F-4877-90E3-7E4F426DB493Q28483069-310D8341-2124-4B81-8AD8-E90E7B04145CQ30992269-8FBAB7E9-0D6C-453A-923C-9AAF43990FAEQ33332501-C53D0274-EED5-450C-AA67-21A6533C9556Q33733004-27365D9E-66E5-40EC-971D-142CB076AF09Q33762602-76FAEDD6-D8A8-4760-98A6-133E0EDFCADBQ34111253-3A3E0D01-7E44-49A5-A943-BE9465574AFBQ34500886-4CDBCD9F-7212-490A-9188-B81337915AB0Q34584940-A8D10B45-3009-4C78-9E6B-FEE850B33B10Q35130398-3906A87F-4546-4824-B8E9-3578E6CF746BQ35291944-500981E2-5A9A-4E80-B509-7BA4547A1F62Q35581924-E6BE70B5-7001-4ECC-B926-DF28CD700D5EQ35607848-F48D2DA3-EC64-460C-AE47-FE9986A91794Q35652431-3D651AD3-4C90-42C8-A6A9-BED8F3E40FE6Q36212750-ED3561AC-F887-48BD-9528-25951C1E4D25Q36359270-B8731F36-E01A-42B0-AC70-1B5187F76515Q36516224-553E8A37-BF2B-4092-A73B-0EF29711FEACQ36671234-63B5319C-079B-4ACC-8362-145CD81F1B36Q36684151-347EEE06-C5D3-44D0-B363-D55D648DD3F3Q36739903-64C74467-612D-4B5A-94E9-17FF3051E21FQ36875890-4A19A0AB-98E1-453F-9956-0757DDB068D0Q37124216-AC7025FF-4223-44D5-A2F4-6925C8DD0A3FQ37967569-A59EB45D-26BF-4E9D-A4AD-B237237AF05BQ38339557-AE1D0AAD-4369-41CA-A221-BA54A015A2A0Q38463228-0C3CAD3B-F240-4179-9E4C-A46794784FC4Q39223286-02EC0694-D8A4-41E2-8D5C-0CC2CFD5F92EQ39367366-BA5A0130-8B44-4CDD-AEB0-0CD321A5E1BBQ39372743-CD63ADF1-0F72-4488-9697-CA79C647F92BQ39422104-18C7BFC0-766E-4076-A028-842A2609D324Q39576850-CA159EEB-4841-4CDE-B50E-E38C34CCAD74Q39587113-265B27AD-8033-4E90-9DCC-37F23F09CA40Q39610772-23E43EFE-F669-42D7-A4AD-9798F37D9FD5Q39624211-7118CB6A-BC13-4E43-8871-EB845550BE0AQ39696626-C1F2B151-1B08-459A-B9A1-1D2DA082F746Q39715054-DBF56FE6-1F78-408F-8677-27EA4A6A98D6
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Nifurtimoks
@sh
Nifurtimoks
@sr
Nifurtimoksi
@fi
Nifurtimox
@de
Nifurtimox
@es
Nifurtimox
@fr
Nifurtimox
@it
Nifurtimox
@nl
Nifurtimox
@ro
Nifurtimox
@vi
type
label
Nifurtimoks
@sh
Nifurtimoks
@sr
Nifurtimoksi
@fi
Nifurtimox
@de
Nifurtimox
@es
Nifurtimox
@fr
Nifurtimox
@it
Nifurtimox
@nl
Nifurtimox
@ro
Nifurtimox
@vi
altLabel
C10H13N3O5S
@fr
NFX
@pl
النيفورتيموكس
@ar
硝呋莫司
@zh
prefLabel
Nifurtimoks
@sh
Nifurtimoks
@sr
Nifurtimoksi
@fi
Nifurtimox
@de
Nifurtimox
@es
Nifurtimox
@fr
Nifurtimox
@it
Nifurtimox
@nl
Nifurtimox
@ro
Nifurtimox
@vi
P31
P672
P486
P592
P6366
P646
P661
P662
P683
P1417
topic/nifurtimox
P2017
CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]
P2067
287.057592
P231
23256-30-6
P232
P233
CC1CS(=O)(=O)CCN1N=CC2=CC=C(O2)[N+](=O)[O-]